Renal and Cardiovascular Effects of Terlipressin in Patients With Cirrhosis and Ascites

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00115947
Recruitment Status : Completed
First Posted : June 27, 2005
Last Update Posted : March 9, 2006
Information provided by:
Hvidovre University Hospital

Brief Summary:

The purpose of this study is to investigate the effect of terlipressin on myocardial perfusion and renal function.

Hypothesis: Significant improvement of renal function reflected by: glomerular filtration rate (GFR), renal blood flow (RBF), excretion of salt and metabolites in the urine and related hormones and peptides in the blood. No effect on the systolic function of the heart.

Condition or disease Intervention/treatment Phase
Cirrhosis Ascites Drug: Terlipressin Phase 2 Phase 3

Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Study Start Date : December 2004
Study Completion Date : January 2006

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Cirrhosis and ascites

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00115947

Hvidovre Hospital
Copenhagen, Hvidovre, Denmark, 2650
Sponsors and Collaborators
Hvidovre University Hospital
Principal Investigator: Aleksander Krag Krag, MD Hvidovre University Hospital Identifier: NCT00115947     History of Changes
Other Study ID Numbers: 2004-000568-29
First Posted: June 27, 2005    Key Record Dates
Last Update Posted: March 9, 2006
Last Verified: June 2005

Additional relevant MeSH terms:
Liver Cirrhosis
Pathologic Processes
Liver Diseases
Digestive System Diseases
Antihypertensive Agents
Vasoconstrictor Agents
Antidiuretic Agents
Natriuretic Agents
Physiological Effects of Drugs